Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:BNXTFNASDAQ:DBVTNASDAQ:LNSRNASDAQ:TOI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNXTFBioNxt Solutions$0.38$0.34$0.11▼$0.43$43.99M0.69,071 shsN/ADBVTDBV Technologies$9.35+0.6%$8.27$2.20▼$12.78$256.10M-0.66190,684 shs66,210 shsLNSRLENSAR$13.58$13.88$3.50▼$17.31$160.14M0.5679,174 shs62,554 shsTOIOncology Institute$3.12+3.7%$2.25$0.13▼$3.50$235.74M0.04927,225 shs899,477 shs10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNXTFBioNxt Solutions0.00%+3.71%+11.76%+8.66%+46.89%DBVTDBV Technologies+0.65%+0.21%+1.96%+122.62%+56.62%LNSRLENSAR0.00%-2.86%-3.21%+24.93%+213.63%TOIOncology Institute+3.65%+16.85%+7.22%+250.52%+551.36%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBNXTFBioNxt SolutionsN/AN/AN/AN/AN/AN/AN/AN/ADBVTDBV Technologies3.1621 of 5 stars3.55.00.00.02.02.50.6LNSRLENSAR2.0083 of 5 stars2.05.00.00.03.62.50.0TOIOncology Institute1.8976 of 5 stars3.53.00.00.01.51.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNXTFBioNxt Solutions 0.00N/AN/AN/ADBVTDBV Technologies 3.00Buy$18.5097.86% UpsideLNSRLENSAR 2.00Hold$15.0010.46% UpsideTOIOncology Institute 3.00Buy$7.00124.36% UpsideCurrent Analyst Ratings BreakdownLatest BNXTF, DBVT, LNSR, and TOI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025DBVTDBV TechnologiesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$15.00 ➝ $21.005/15/2025TOIOncology InstituteBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$7.005/5/2025DBVTDBV TechnologiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $16.005/1/2025DBVTDBV TechnologiesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $15.003/24/2025LNSRLENSARBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/24/2025LNSRLENSARLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$16.00 ➝ $15.002/28/2025LNSRLENSARLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $16.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNXTFBioNxt Solutions$280K157.11N/AN/A($0.04) per share-9.50DBVTDBV Technologies$15.73M16.28N/AN/A$7.27 per share1.29LNSRLENSAR$57.07M2.81N/AN/A$2.97 per share4.57TOIOncology Institute$403.15M0.58N/AN/A$0.77 per share4.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNXTFBioNxt Solutions-$5.72M-$0.04N/A∞N/A-15,638.71%N/A-683.78%N/ADBVTDBV Technologies-$72.73M-$4.92N/AN/AN/A-815.73%-106.07%-76.17%7/29/2025 (Estimated)LNSRLENSAR-$14.38M-$4.85N/A∞N/A-34.03%-49.02%-21.12%8/6/2025 (Estimated)TOIOncology Institute-$83.07M-$0.70N/A∞N/A-17.63%-186.83%-34.58%8/11/2025 (Estimated)Latest BNXTF, DBVT, LNSR, and TOI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025TOIOncology InstituteN/A-$0.18N/A-$0.21N/A$104.41 million5/8/2025Q1 2025LNSRLENSAR-$0.1550-$2.32-$2.1650-$2.32$13.40 million$11.53 million4/11/2025Q4 2024DBVTDBV TechnologiesN/A-$1.10N/A-$1.10N/A$0.51 million3/24/2025Q4 2024TOIOncology Institute-$0.08-$0.14-$0.06-$0.14$109.15 million$100.27 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBNXTFBioNxt SolutionsN/AN/AN/AN/AN/ADBVTDBV TechnologiesN/AN/AN/AN/AN/ALNSRLENSARN/AN/AN/AN/AN/ATOIOncology InstituteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNXTFBioNxt SolutionsN/A0.040.04DBVTDBV TechnologiesN/A2.222.22LNSRLENSARN/A3.372.10TOIOncology Institute5.912.492.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNXTFBioNxt SolutionsN/ADBVTDBV Technologies71.74%LNSRLENSAR40.15%TOIOncology Institute36.86%Insider OwnershipCompanyInsider OwnershipBNXTFBioNxt SolutionsN/ADBVTDBV Technologies1.44%LNSRLENSAR38.52%TOIOncology Institute8.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBNXTFBioNxt Solutions20115.76 millionN/ANot OptionableDBVTDBV Technologies8027.39 million20.18 millionOptionableLNSRLENSAR11011.79 million7.14 millionOptionableTOIOncology Institute66075.56 million68.38 millionNot OptionableBNXTF, DBVT, LNSR, and TOI HeadlinesRecent News About These CompaniesInsider Selling: The Oncology Institute, Inc. (NASDAQ:TOI) Director Sells 203,532 Shares of StockMay 23, 2025 | insidertrades.comOncology Institute First Quarter 2025 Earnings: US$0.25 loss per share (vs US$0.22 loss in 1Q 2024)May 16, 2025 | finance.yahoo.comOncology Institute Shares Rise After Higher 1Q RevenueMay 15, 2025 | marketwatch.comThe Oncology Institute Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 GuidanceMay 15, 2025 | finanznachrichten.deTOI reaffirms 2025 guidance with $460M–$480M revenue target as capitation contracts fuel growthMay 15, 2025 | msn.comQ1 2025 Oncology Institute Inc Earnings CallMay 15, 2025 | finance.yahoo.comThe Oncology Institute, Inc. (TOI) Q1 2025 Earnings Call TranscriptMay 15, 2025 | seekingalpha.comThe Oncology Institute Welcomes Dr. Jeff Langsam as Chief Clinical OfficerMay 14, 2025 | globenewswire.comTopicus.com Inc. Announces Election of Members of the Board of DirectorsMay 13, 2025 | globenewswire.comThe Oncology Institute to Participate at the B. Riley Securities 25th Annual Institutional Investor ConferenceMay 13, 2025 | globenewswire.comWhy The Oncology Institute, Inc.’s (TOI) Stock Is Down 5.48%May 10, 2025 | aaii.comConstellation Software Inc. and Topicus.Com Inc. Announce Results for Topicus.com Inc. for the First Quarter Ended March 31, 2025May 7, 2025 | globenewswire.comThe Oncology Institute: Insiders Buy Up Big While Valuations Are MurkyMay 6, 2025 | seekingalpha.comWhy The Oncology Institute, Inc.’s (TOI) Stock Is Down 6.07%May 5, 2025 | aaii.comThe Oncology Institute, Inc.'s (NASDAQ:TOI) largest shareholders are retail investors with 40% ownership, private equity firms own 24%May 5, 2025 | uk.finance.yahoo.comTopicus.com Inc. Defers Release Date for First Quarter ResultsMay 1, 2025 | globenewswire.comThe Oncology Institute Announces First Quarter 2025 Earnings Release Date and Conference CallApril 23, 2025 | globenewswire.comTopicus.com Inc. Announces Release Date for First Quarter ResultsApril 14, 2025 | globenewswire.comWhy The Oncology Institute, Inc.’s (TOI) Stock Is Up 9.33%April 10, 2025 | aaii.comWhy The Oncology Institute, Inc.’s (TOI) Stock Is Up 17.46%April 3, 2025 | aaii.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBNXTF, DBVT, LNSR, and TOI Company DescriptionsBioNxt Solutions OTCMKTS:BNXTF$0.38 0.00 (0.00%) As of 05/27/2025BioNxt Solutions Inc. engages in generation drug formulations and delivery system in Korea, Austria, Germany, and Switzerland. The company provides drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications. It offers point-of-care diagnostic, including covid-19 PCR diagnostic kit, a covid rapid test; peri-implantitis Oral Biosensor, allows early detection of infection associated with dental implants; and H1N1 (Swine Flu) and H5N1 (Avian Flu) oral biosensors for early detection of highly pathogenic influenza a strains. In addition, the company offers psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. Further, it provides analytical testing and consulting services. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.DBV Technologies NASDAQ:DBVT$9.35 +0.06 (+0.65%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$9.32 -0.03 (-0.32%) As of 05/28/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.LENSAR NASDAQ:LNSR$13.58 0.00 (0.00%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$13.58 +0.01 (+0.04%) As of 05/28/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.Oncology Institute NASDAQ:TOI$3.12 +0.11 (+3.65%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$3.15 +0.03 (+0.96%) As of 05/28/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
